Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pembrolizumab versus placebo after complete resection of high-risk Stage III melanoma
2014-004944-37Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous melanoma (CM) and melanoma comparing Pembrolizumab adjuvant arm with Placebo arm (2 arms). Primary endpoint: Recurrence-free survival. Started Feb 2015; status: active.
02
Drugs
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2014-004944-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004944-37.